ArticleCell death & disease2026
NUP93 facilitates the nuclear import of SOX2 to activate G3BP1 transcription and impairs gemcitabine response in pancreatic cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gemcitabine is a cornerstone chemotherapeutic for pancreatic ductal adenocarcinoma (PDAC); however, the frequent development of resistance compromises its efficacy and poses a significant challenge to patient prognosis. Here, we report that nuclear pore protein NUP93 is upregulated in PDAC and correlates with poor patient survival. Functional studies demonstrated that NUP93 promotes PDAC cell proliferation and confers gemcitabine resistance by enhancing DNA damage repair. Mechanistically, NUP93 interacts with the transcription factor SOX2 by recognizing its nuclear localization sequence and facilitates its nuclear import. Nuclear SOX2 transcriptionally activates the key stress granule component G3BP1 by directly binding to its promoter. Subsequently, G3BP1 stabilizes the mRNA of RAD51, a crucial homologous recombination repair factor, thereby promoting DNA damage repair and gemcitabine resistance. In vivo, disruption of the NUP93/SOX2/G3BP1 axis suppressed tumor growth and synergized with gemcitabine. Our findings unveil the novel NUP93-SOX2-G3BP1 signaling axis as a critical driver of gemcitabine resistance in PDAC, presenting a promising therapeutic target for overcoming chemoresistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.